Anthem Biosciences Limited announced the outcome of its Board Meeting held on February 05, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. These results were reviewed and recommended by the Audit Committee. Additionally, the Board approved the allotment of 1,03,800 equity shares of face value Rs. 2 each to eligible employees under the Anthem Employee Stock Option Plan 2024. This allotment increases the company's paid-up equity share capital from Rs. 1,12,32,20,102 to Rs. 1,12,34,27,702. The financial results indicate a revenue from operations of Rs. 4,165.75 crore for the standalone entity and Rs. 4,231.53 crore for the consolidated entity for the quarter ended December 31, 2025. For the nine months ended December 31, 2025, standalone revenue was Rs. 15,068.12 crore and consolidated revenue was Rs. 15,133.89 crore. The company also reported an exceptional item of Rs. 249.84 crore in standalone results and Rs. 253.71 crore in consolidated results, related to the assessment of new Labour Codes.
